Intrahepatic transcriptomics reveals gene signatures in chronic hepatitis B patients responded to interferon therapy. Issue 1 (31st December 2022)

• Record Type: Journal Article
• Authors: Li, Ning; Yu, Kangkang; Dong, Minhui; Wang, Jinyu; Yang, Feifei; Zhu, Haoxiang; Yu, Jie; Yang, Jingshu; Xie, Wentao; Mitra, Bidisha; Mao, Richeng; Wu, Feizhen; Guo, Haitao; Zhang, Jiming
• Is Part Of: Emerging microbes & infections. Volume 11:Issue 1(2022)
• Page Start: 1876
• Page End: 1889
• Publication Date: 2022-12-31
• Subjects: Chronic hepatitis B -- interferon therapy -- liver biopsy -- transcriptome -- HBeAg; Medical microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 616.9041
• DOI: 10.1080/22221751.2022.2100831
• Languages: English
• ISSNs: 2222-1751

Abstract

ABSTRACT: Chronic hepatitis B virus (HBV) infection remains a substantial public health burden worldwide. Alpha-interferon (IFNα) is one of the two currently approved therapies for chronic hepatitis B (CHB), to explore the mechanisms underlying IFNα treatment response, we investigated baseline and 24-week on-treatment intrahepatic gene expression profiles in 21 CHB patients by mRNA-seq. The data analyses demonstrated that PegIFNα treatment significantly induced antiviral responses. Responders who achieved HBV DNA loss and HBeAg or HBsAg seroconversion displayed higher fold change and larger number of up-regulated interferon-stimulated genes (ISGs). Interestingly, lower expression levels of certain ISGs were observed in responders in their baseline biopsy samples. In HBeAg+ patients, non-responders had relative higher baseline HBeAg levels than responders. More importantly, HBeAg− patients showed higher HBsAg loss rate than HBeAg+ patients. Although a greater fold change of ISGs was observed in HBeAg− patients than HBeAg+ patients, upregulation of ISGs in HBeAg+ responders exceeded HBeAg− responders. Notably, PegIFNα treatment increased monocyte and mast cell infiltration, but decreased CD8 T cell and M1 macrophage infiltration in both responders and non-responders, while B cell infiltration was increased only in responders. Moreover, co-expression analysis identified ribosomal proteins as critical players in antiviral response. The data also indicate that IFNα may influence the production of viral antigens associated with endoplasmic reticulum. Collectively, the intrahepatic transcriptome analyses in this study enriched our understanding of IFN-mediated antiviral effects in CHB patients and provided novel insights into the development of potential strategies to improve IFNα therapy.